Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512514 | 0.92 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512516 | 0.92 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512647 | 0.92 | KDM1A (0.51) | KDM1A | |
| SCHEMBL20512753 | 0.90 | KDM1A (0.51) | KDM1A | |
| SCHEMBL23496011 | 0.82 | KDM1A (0.48) | KDM1A | |
| SCHEMBL20512481 | 0.82 | KDM1A (0.48) | KDM1A | |
| SCHEMBL21824282 | 0.82 | KDM1A (0.51) | KDM1A | |
| SCHEMBL30568897 | 0.79 | KDM1A (0.69) | KDM1A | |
| SCHEMBL29927055 | 0.79 | KDM1A (0.69) | KDM1A | |
| SCHEMBL30568919 | 0.78 | KDM1A (0.70) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | KDM1A 3/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | KDM1A 7/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.